Global Preclinical CRO Market Outlook 2025–2030: Trends, Drivers, and Investment

The global Preclinical Contract Research Organization (CRO) market was valued at USD 8.64 billion in 2024 and is projected to reach USD 9.73 billion by 2025, expanding further to USD 17.61 billion by 2030 at a compound annual growth rate (CAGR) of 12.6%. The market is evolving as a critical early-stage segment of the drug development ecosystem, providing GLP-compliant toxicology, ADME/PK studies, bioanalytical services, disease models, and bespoke assay development. Growth is driven by rising healthcare expenditure, regulatory support for predictive toxicology and new approach methodologies (NAMs), and increasing demand for biologics, gene, and cell therapy programs. Integration of AI-driven computational toxicology, organ-on-chip platforms, and human-cell derived systems is reshaping service offerings. Regional expansion, strategic partnerships, and M&A activities further strengthen market potential. This study provides comprehensive insights into market segmentation, regional outlook, competitive landscape, and investment opportunities, offering a roadmap for stakeholders to navigate the evolving preclinical CRO industry.